VivoSeq
Other

LCH

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

LCH is an early-stage landscape with 0 programs across 2 companies. The most active players are AstraZeneca, Athera Biotechnologies AB.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalA

Athera Biotechnologies AB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed8 · 80%
Terminated1 · 10%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT01205867·22 enrolled
High-Resolution Solid-State Manometry of the Effect of Succinylcholine on Barrier Pressure
Completed·—·Phase 4·NCT05556408·14 enrolled
Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency
Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00006061·1 enrolled
A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly
Completed·BBaxalta now part of Shire·Phase 1·NCT00333528·8 enrolled
Effects of Cisatracurium on Sccinylcholine-induced Fasciculations
Completed·—·Phase 3·NCT02502032·87 enrolled
Fade Upon TOF Stimulation Induced by Succinylcholine
Completed·UUniversity of Toledo Health Science Campus·Phase 4·NCT02425449·19 enrolled
Effect of Selenium on Succinylcholine-Induced POM
Completed·—·Phase 2/3·NCT03476044·80 enrolled
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
Completed·UUniversity of Roma La Sapienza·N/A·NCT02645461·50 enrolled
Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Terminated·AAthera Biotechnologies AB·Phase 2·NCT03320265·10 enrolled
Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
Unknown status·SSeoul National University Hospital·N/A·NCT02063269·70 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)